SCHEMBL13615447

SCHEMBL13615447

CCOC(=O)/C(C(C)=O)=C(/N)c1ccc(OC)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
HTT P42858 1/20 0.56
MAPT P10636 2/20 0.54
CA1 P00915 3/20 0.49
CA2 P00918 3/20 0.49
PARP10 Q53GL7 3/20 0.49
PARP1 P09874 1/20 0.49
PARP2 Q9UGN5 1/20 0.49
PARP4 Q9UKK3 1/20 0.49
HDAC3 O15379 2/20 0.47
HDAC4 P56524 2/20 0.47
HDAC1 Q13547 2/20 0.47
HDAC7 Q8WUI4 2/20 0.47
HDAC2 Q92769 2/20 0.47
HDAC10 Q969S8 2/20 0.47
HDAC11 Q96DB2 2/20 0.47
HDAC8 Q9BY41 2/20 0.47
HDAC6 Q9UBN7 2/20 0.47
HDAC9 Q9UKV0 2/20 0.47
HDAC5 Q9UQL6 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7072196 0.92 ALDH1A1 (0.60) ALDH1A1HTTMAPTCA1CA2
SCHEMBL3403489 0.84 MAPT (0.48) ALDH1A1HTTMAPTCES2CES1
SCHEMBL22257020 0.84 KMT2A (0.48) ALDH1A1HTTMAPTCES2CES1
SCHEMBL3403487 0.84 MAPT (0.48) ALDH1A1HTTMAPTCES2CES1
SCHEMBL3405926 0.84 SMN1; SMN2 (0.47) ALDH1A1HTTMAPTCYP19A1LMNA
SCHEMBL3405931 0.84 SMN1; SMN2 (0.47) ALDH1A1HTTMAPTCYP19A1LMNA
SCHEMBL3398766 0.83 KMT2A (0.58) ALDH1A1HTTMAPTCYP19A1KDM4E
SCHEMBL3398770 0.83 KMT2A (0.58) ALDH1A1HTTMAPTCYP19A1KDM4E
SCHEMBL7193063 0.80 ALDH1A1 (0.56) ALDH1A1HTTMAPTCA1CA2
SCHEMBL27763351 0.78 KMT2A (0.48) ALDH1A1HTTMAPTCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612069-B2 Acyl guanidines as beta-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-11-03 US disclosed
US-7273882-B2 Aminoacetamide acyl guanidines as β-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-09-25 US disclosed
US-7273882-B2 Aminoacetamide acyl guanidines as β-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-09-25 US disclosed
US-20070015754-A1 Acyl guanidines as beta-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-01-18 US disclosed
US-20070015754-A1 Acyl guanidines as beta-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2007-01-18 US disclosed
WO-2007002220-A2 AMINOACETAMIDE ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015754-A1 Acyl guanidines as beta-secretase inhibitors BACE1, APP, BACE2 ALDH1A1 2144/4885HTT 453/4885MAPT 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.